Aurobindo Pharma USA, a subsidiary of India-based Aurobindo Pharma, has signed a definitive agreement to acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.
Founded in 1942 and headquartered in Trevose, Pa., Lannett manufactures and supplies complex generic pharmaceuticals, including non-opioid controlled substances and liquid formulations. The company has a strong presence in the attention-deficit/hyperactivity disorder (ADHD) treatment market and operates a 425,000-square-foot cGMP facility in Seymour, Ind., with an annual capacity of approximately 3.6 billion tablets.
The acquisition aligns with Aurobindo’s strategy to expand its U.S. manufacturing base, diversify into high-value therapeutic areas and increase domestic production capabilities amid rising political pressure for onshore pharmaceutical manufacturing. President Donald Trump has recently reiterated plans to impose steep tariffs, up to 250%, on imported drugs.
Aurobindo said the deal will provide access to Lannett’s complementary product portfolio, contract development and manufacturing organization (CDMO) business, and excess capacity for future growth. The company currently has limited exposure to ADHD therapeutics, a U.S. market valued at $15 billion in 2024 and projected to reach $18.6 billion by 2030.
The transaction is subject to regulatory approvals, including clearance from the U.S. Federal Trade Commission, and is expected to close within 8 to 12 months. It will be funded entirely through cash consideration.
